Yarrow Bioscience
YARW
63 hedge funds and large institutions have $64M invested in Yarrow Bioscience in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 11 increasing their positions, 20 reducing their positions, and 34 closing their positions.
815% more call options, than puts
Call options by funds: $366K | Put options by funds: $40K
8.37% less ownership
Funds ownership: 43.88% → 35.51% (-8.4%)
22% less funds holding
Funds holding: 81 → 63 (-18)
45% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 20
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
53% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 34
58% less capital invested
Capital invested by funds: $154M → $64M (-$90.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$3.23M |
| 2 |
Millennium Management
New York
|
+$2.87M |
| 3 |
Renaissance Technologies
New York
|
+$1.37M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$930K |
| 5 |
BCV
Banque Cantonale Vaudoise
Lausanne,
Switzerland
|
+$879K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$11.3M |
| 2 |
PA
Perceptive Advisors
New York
|
-$4.4M |
| 3 |
Axa
Paris,
France
|
-$3.35M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.87M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.61M |
YARW Hedge Fund Activity: Q2 2021 in Review
63 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience (YARW) for Q2 2021, worth a combined $64M — down 58% from $154M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of YARW and 16 opened new positions — a net loss of 18 holders — while 20 trimmed existing stakes and 11 added.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $3.23M. The largest seller was BlackRock, cutting an estimated $11.3M.
- 63 institutional investors held Yarrow Bioscience (YARW) as of Q2 2021, down from 81 in Q1 2021.
- Funds reported $64M of Yarrow Bioscience stock for Q2 2021, down 58% quarter-over-quarter.
- 16 funds opened new Yarrow Bioscience positions in Q2 2021 and 34 closed out, a net change of -18 holders.
- The largest Yarrow Bioscience buyer in Q2 2021 was 683 Capital Management, an estimated $3.23M added.
- The largest Yarrow Bioscience seller in Q2 2021 was BlackRock, an estimated $11.3M sold.
Based on aggregated 13F filings for Q2 2021.